Literature DB >> 29320652

Multiple Sclerosis.

Daniel S Reich1, Claudia F Lucchinetti1, Peter A Calabresi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29320652      PMCID： PMC6942519          DOI： 10.1056/NEJMra1401483

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  91 in total

Review 1.  Oligodendrocyte Development and Plasticity.

Authors:  Dwight E Bergles; William D Richardson
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-08-20       Impact factor: 10.005

2.  Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history.

Authors:  J O Harris; J A Frank; N Patronas; D E McFarlin; H F McFarland
Journal:  Ann Neurol       Date:  1991-05       Impact factor: 10.422

Review 3.  Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

Authors:  Gavin Giovannoni; Benjamin Turner; Sharmilee Gnanapavan; Curtis Offiah; Klaus Schmierer; Monica Marta
Journal:  Mult Scler Relat Disord       Date:  2015-05-08       Impact factor: 4.339

Review 4.  Biomarkers in multiple sclerosis.

Authors:  William J Housley; David Pitt; David A Hafler
Journal:  Clin Immunol       Date:  2015-07-02       Impact factor: 3.969

5.  Axonal transection in the lesions of multiple sclerosis.

Authors:  B D Trapp; J Peterson; R M Ransohoff; R Rudick; S Mörk; L Bö
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

6.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Authors:  Robert J Fox; Christopher S Coffey; Merit E Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C Klawiter; Kazuko Matsuda; Michelle McGovern; Robin Conwit; Robert Naismith; Akshata Ashokkumar; Robert Bermel; Dixie Ecklund; Maxine Koepp; Jeffrey Long; Sneha Natarajan; Srividya Ramachandran; Thomai Skaramagas; Brenda Thornell; Jon Yankey; Mark Agius; Khurram Bashir; Bruce Cohen; Patricia Coyle; Silvia Delgado; Dana Dewitt; Angela Flores; Barbara Giesser; Myla Goldman; Burk Jubelt; Neil Lava; Sharon Lynch; Augusto Miravalle; Harold Moses; Daniel Ontaneda; Jai Perumal; Michael Racke; Pavle Repovic; Claire Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Gutman; Vijayshree Yadav; Aram Zabeti
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

7.  Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.

Authors:  Jeremy Chataway; Nadine Schuerer; Ali Alsanousi; Dennis Chan; David MacManus; Kelvin Hunter; Val Anderson; Charles R M Bangham; Shona Clegg; Casper Nielsen; Nick C Fox; David Wilkie; Jennifer M Nicholas; Virginia L Calder; John Greenwood; Chris Frost; Richard Nicholas
Journal:  Lancet       Date:  2014-03-19       Impact factor: 79.321

8.  The formation of inflammatory demyelinated lesions in cerebral white matter.

Authors:  Pietro Maggi; Sheila M Cummings Macri; María I Gaitán; Emily Leibovitch; Jillian E Wholer; Heather L Knight; Mary Ellis; Tianxia Wu; Afonso C Silva; Luca Massacesi; Steven Jacobson; Susan Westmoreland; Daniel S Reich
Journal:  Ann Neurol       Date:  2014-08-21       Impact factor: 10.422

9.  Clostridium perfringens Epsilon Toxin Causes Selective Death of Mature Oligodendrocytes and Central Nervous System Demyelination.

Authors:  Jennifer R Linden; Yinghua Ma; Baohua Zhao; Jason Michael Harris; Kareem Rashid Rumah; Nicole Schaeren-Wiemers; Timothy Vartanian
Journal:  MBio       Date:  2015-06-16       Impact factor: 7.867

10.  Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis.

Authors:  S Jarius; F B König; I Metz; K Ruprecht; F Paul; W Brück; B Wildemann
Journal:  J Neuroinflammation       Date:  2017-08-29       Impact factor: 8.322
View more
  488 in total

1.  Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.

Authors:  E D'Amico; A Zanghì; M Sciandra; G Borriello; G Callari; A Gallo; G Salemi; S Cottone; M Buccafusca; P Valentino; R B Bossio; L M E Grimaldi; C Pozzilli; G Tedeschi; M Zappia; F Patti
Journal:  J Neurol       Date:  2018-12-04       Impact factor: 4.849

2.  Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study.

Authors:  Anna M Pietroboni; Tiziana Carandini; Laura Dell'Arti; Francesca Bovis; Annalisa Colombi; Milena A De Riz; Elena Casazza; Elisa Scola; Chiara Fenoglio; Andrea Arighi; Giorgio G Fumagalli; Fabio Triulzi; Daniela Galimberti; Francesco Viola; Elio Scarpini
Journal:  Neurol Sci       Date:  2020-04-30       Impact factor: 3.307

Review 3.  Imaging Brain Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy.

Authors:  Lydia M Le Page; Caroline Guglielmetti; Celine Taglang; Myriam M Chaumeil
Journal:  Trends Neurosci       Date:  2020-04-08       Impact factor: 13.837

4.  Headache in the course of multiple sclerosis: a prospective study.

Authors:  Marcel Gebhardt; Peter Kropp; Frank Hoffmann; Uwe K Zettl
Journal:  J Neural Transm (Vienna)       Date:  2018-11-30       Impact factor: 3.575

5.  Deficiency of Socs3 leads to brain-targeted EAE via enhanced neutrophil activation and ROS production.

Authors:  Zhaoqi Yan; Wei Yang; Luke Parkitny; Sara A Gibson; Kevin S Lee; Forrest Collins; Jessy S Deshane; Wayne Cheng; Amy S Weinmann; Hairong Wei; Hongwei Qin; Etty N Benveniste
Journal:  JCI Insight       Date:  2019-04-02

6.  Comparison of Multiple Sclerosis Cortical Lesion Types Detected by Multicontrast 3T and 7T MRI.

Authors:  J Maranzano; M Dadar; D A Rudko; D De Nigris; C Elliott; J S Gati; S A Morrow; R S Menon; D L Collins; D L Arnold; S Narayanan
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-20       Impact factor: 3.825

7.  Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis.

Authors:  Angeliki G Filippatou; Jeffrey Lambe; Elias S Sotirchos; Kathryn C Fitzgerald; Andrew Aston; Olwen C Murphy; Nicole Pellegrini; Nicholas Fioravante; Hunter Risher; Esther Ogbuokiri; Ohemaa Kwakyi; Brandon Toliver; Simidele Davis; Nicholas Luciano; Ciprian Crainiceanu; Jerry L Prince; Ellen M Mowry; Peter A Calabresi; Shiv Saidha
Journal:  Mult Scler       Date:  2020-04-16       Impact factor: 6.312

8.  Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.

Authors:  Richard K Burt; Roumen Balabanov; Joachim Burman; Basil Sharrack; John A Snowden; Maria Carolina Oliveira; Jan Fagius; John Rose; Flavia Nelson; Amilton Antunes Barreira; Kristina Carlson; Xiaoqiang Han; Daniela Moraes; Amy Morgan; Kathleen Quigley; Kimberly Yaung; Regan Buckley; Carri Alldredge; Allison Clendenan; Michelle A Calvario; Jacquelyn Henry; Borko Jovanovic; Irene B Helenowski
Journal:  JAMA       Date:  2019-01-15       Impact factor: 56.272

9.  Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.

Authors:  Andrea Manterola; Ana Bernal-Chico; Raffaela Cipriani; Manuel Canedo-Antelo; Álvaro Moreno-García; Mar Martín-Fontecha; Fernando Pérez-Cerdá; María Victoria Sánchez-Gómez; Silvia Ortega-Gutiérrez; J Mark Brown; Ku-Lung Hsu; Benjamin Cravatt; Carlos Matute; Susana Mato
Journal:  Biochem Pharmacol       Date:  2018-08-01       Impact factor: 5.858

Review 10.  Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs.

Authors:  Christine Lebrun; Fanny Rocher
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.